New paper in Mol Pharm (ASPET): Molecular Envelope Technology - first demonstration of highly concentrated subcutaneous formulations with hyaluronidase coated nanoparticles. Encapsulated CUDC-101 successfully suppresses pancreatic cancer in tumour models. bit.ly/3cg35pDon

Excellent statement and practical steps from IoD iod.com/news-campaigns…

Nanomerics receives pIND guidance from the US FDA for NM134 for the treatment of an undisclosed, potentially sight threatening eye disease. bit.ly/3e8v22C

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray biorxiv.org/cgi/content/sh… #bioRxiv

Nanomerics Molecular Mask Technology (MMT): SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray biorxiv.org/content/10.110…

Original tween about our collaboration with the teams Uniwersytet Jagielloński and UCL

Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication. Press release update with more details bit.ly/3mmD8cj #COVID19 #molecular_mask

Nanomerics receives double milestone payment from Virpax® Pharmaceuticals, Inc. (Nasdaq: VRPX) for Envelta™️ and MMS019, an antiviral nasal spray accesswire.com/viewarticle.as….

Congratulations to our 50 new Fellows announced today Find out more about these prominent biomedical and health scientists and see the full list on our website: ow.ly/nchU50EIJ0a #AMSFellows2021

Nanomerics CSO Prof I F Uchegbu elected a fellow of the Academy of Medical Sciences Academy of Medical Sciences bit.ly/3ffgtNj

Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology bit.ly/3oJpt1v Pharmaceutics MDPI #DrugDelivery

Nanomerics CSO Ijeoma Uchegbu appointed to Wellcome's board Wellcome wellcome.org/news/ijeoma-uc…

Nanomerics developed NIH-backed nasal nonaddictive pain prospect clears early test fiercepharma.com/drug-delivery/…

We applaud this recent statement by Dr. Robert Califf, FDA Commissioner, about supporting development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.

Nanomerics Awarded an MHRA Innovation Passport for OC134 accesswire.com/viewarticle.as…

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada The patent together with others takes protection of Nanomerics' ocular Molecular Envelope Technology (MET) franchise, in Canada, to 2035 accesswire.com/viewarticle.as…

Thanks Nanomerics for hosting participants on our #RSCBroadeningHorizons programme, which supports students from Black & minority ethnic backgrounds to launch a #ChemCareer, including Kholil Rahman, a postgraduate student at The University of Manchester🧵 rsc.li/3MZjHV6

We are pleased to have been selected to present our MET platform to the science and technology staff at the Defense Threat Reduction Agency (DTRA), Defense Advanced Research Projects Agency (DARPA) in addition to members of the Army, Navy and other military branches and Federal

We are honored to ring the closing bell on July 24th and recognize the hard work and outstanding contributions from our entire team. We have made tremendous progress in moving our product candidates forward and expect to be in human clinical trials in 2024.

Nanomerics wins the United Kingdom King’s Award for Enterprise - Innovation 2024 The King's Awards bit.ly/nmx_KAE2024